Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

This publication has 22 references indexed in Scilit:

• Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
  JAMA Network Open, 2023
• Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge
  JAMA Network Open, 2022
• Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
  The Lancet Respiratory Medicine, 2022
• Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study
  The Lancet Global Health, 2022
• Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
  The Lancet, 2022
• Antibody evasion properties of SARS-CoV-2 Omicron sublineages
  Nature, 2022
• Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis
  The Lancet, 2022
• Severe Covid-19
  New England Journal of Medicine, 2020
• Mild or Moderate Covid-19
  New England Journal of Medicine, 2020
• Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
  JAMA, 2020